INMED PHARMACEUTICALS INC. Cash
INMED PHARMACEUTICALS INC. (INM) had Cash of $6.57 million as of 2024-06-30, per its 10-K filed 2024-09-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:Cash · last filed 2024-09-30
- 2024-06-30: Cash $6.57M.
- 2023-06-30: Cash $8.91M; Cash as first filed $9.00M.
- 2023-03-31: Cash $8.80M.
- 2022-12-31: Cash $11.02M.
| Period end | Cash | Cash as first filed |
|---|---|---|
| 2024-06-30 | $6.57M 10-K · filed 2024-09-30 | |
| 2023-06-30 | $8.91M 10-K · filed 2024-09-30 | $9.00M 10-K · filed 2023-09-29 |
| 2023-03-31 | $8.80M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $11.02M 10-Q · filed 2023-02-17 | |
| 2022-09-30 | $8.06M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $5.09M 10-Q · filed 2023-05-15 | |
| 2022-03-31 | $4.48M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $8.31M 10-Q · filed 2022-02-14 | |
| 2021-09-30 | $7.11M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $7.05M 10-K · filed 2022-09-23 | |
| 2021-03-31 | $3.46M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $3.04M 10-Q · filed 2021-02-11 | |
| 2020-09-30 | $3.85M 10-Q · filed 2020-12-17 | |
| 2020-06-30 | $4.31M 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |